EyePointEYPT
Fair Value
US$20
Share price07 Jan
US$14.7526.3% undervalued intrinsic discount
1Y33.00%
7D6.19%
Late Stage Ocular Therapy Risks Will Eventually Reward Sustained Release Retinal Franchise Potential
AN
Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Published
07 Jan 26
Views
14
Not Invested